Brain Tumor Res Treat.  2022 Apr;10(2):94-100. 10.14791/btrt.2022.0003.

Recent Updates on Radiation Therapy for Pediatric Optic Pathway Glioma

Affiliations
  • 1Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Abstract

Optic pathway glioma (OPG) is a rare tumor located in optic nerve, optic tract, or optic chiasm. Treatment options for OPG include surgery, radiation therapy (RT), and chemotherapy. Although RT may provide favorable long-term outcomes in manner of either adjuvant or salvage aim, chemotherapy-first approach is increasingly performed due to possible late effects of RT. Proton beam RT may allow normal tissue sparing of radiation exposure compared to conventional X-ray treatment. Therefore, proton beam RT is expected to reduce complications from RT. This review discusses the recent updates on oncologic outcomes of OPG, late toxicities following RT, and compares the outcomes between X-ray treatment and proton beam RT.

Keyword

Brain Neoplasms; Child; Optic glioma; Radiation therapy; Proton radiotherapy

Figure

  • Fig. 1 Plan comparison according to radiation therapy (RT) modality. RT planning using 2-dimensional photon RT (A), 3-diensional conformal photon RT (B), intensity-modulated photon RT (C), and proton beam RT (D). Proton beam have better dose conformity to target area and lower radiation dose distribution to normal brain (e.g., temporal lobe) than photon RT.


Reference

1. Jahraus CD, Tarbell NJ. Optic pathway gliomas. Pediatr Blood Cancer. 2006; 46:586–596. PMID: 16411210.
2. Listernick R, Charrow J, Greenwald M, Mets M. Natural history of optic pathway tumors in children with neurofibromatosis type 1: a longitudinal study. J Pediatr. 1994; 125:63–66. PMID: 8021787.
3. Hoffman HJ, Soloniuk DS, Humphreys RP, Drake JM, Becker LE, De Lima BO, et al. Management and outcome of low-grade astrocytomas of the midline in children: a retrospective review. Neurosurgery. 1993; 33:964–971. PMID: 8134009.
4. Oh KS, Hung J, Robertson PL, Garton HJ, Muraszko KM, Sandler HM, et al. Outcomes of multidisciplinary management in pediatric low-grade gliomas. Int J Radiat Oncol Biol Phys. 2011; 81:e481–e488. PMID: 21470783.
5. Raikar SS, Halloran DR, Elliot M, McHugh M, Patel S, Gauvain KM. Outcomes of pediatric low-grade gliomas treated with radiation therapy: a single-institution study. J Pediatr Hematol Oncol. 2014; 36:e366–e370. PMID: 24714505.
6. Yock TI, Tarbell NJ. Technology insight: proton beam radiotherapy for treatment in pediatric brain tumors. Nat Clin Pract Oncol. 2004; 1:97–103. PMID: 16264827.
7. Gondi V, Yock TI, Mehta MP. Proton therapy for paediatric CNS tumours-improving treatment-related outcomes. Nat Rev Neurol. 2016; 12:334–345. PMID: 27197578.
8. Lim DH. Radiation therapy for pediatric brain tumors. J Korean Med Assoc. 2012; 55:447–453.
9. Tsang DS, Murphy ES, Merchant TE. Radiation therapy for optic pathway and hypothalamic low-grade gliomas in children. Int J Radiat Oncol Biol Phys. 2017; 99:642–651. PMID: 29280458.
10. Cherlow JM, Shaw DWW, Margraf LR, Bowers DC, Huang J, Fouladi M, et al. Conformal radiation therapy for pediatric patients with low-grade glioma: results from the children’s oncology group phase 2 study ACNS0221. Int J Radiat Oncol Biol Phys. 2019; 103:861–868. PMID: 30419305.
11. Tao ML, Barnes PD, Billett AL, Leong T, Shrieve DC, Scott RM, et al. Childhood optic chiasm gliomas: radiographic response following radiotherapy and long-term clinical outcome. Int J Radiat Oncol Biol Phys. 1997; 39:579–587. PMID: 9336136.
Article
12. Cappelli C, Grill J, Raquin M, Pierre-Kahn A, Lellouch-Tubiana A, Terrier-Lacombe MJ, et al. Long-term follow up of 69 patients treated for optic pathway tumours before the chemotherapy era. Arch Dis Child. 1998; 79:334–338. PMID: 9875044.
13. Marcus KJ, Goumnerova L, Billett AL, Lavally B, Scott RM, Bishop K, et al. Stereotactic radiotherapy for localized low-grade gliomas in children: final results of a prospective trial. Int J Radiat Oncol Biol Phys. 2005; 61:374–379. PMID: 15667955.
14. Indelicato DJ, Rotondo RL, Uezono H, Sandler ES, Aldana PR, Ranalli NJ, et al. Outcomes following proton therapy for pediatric low-grade glioma. Int J Radiat Oncol Biol Phys. 2019; 104:149–156. PMID: 30684665.
15. Combs SE, Schulz-Ertner D, Moschos D, Thilmann C, Huber PE, Debus J. Fractionated stereotactic radiotherapy of optic pathway gliomas: tolerance and long-term outcome. Int J Radiat Oncol Biol Phys. 2005; 62:814–819. PMID: 15936565.
16. Acharya S, Quesada S, Coca K, Richardson C, Hoehn ME, Chiang J, et al. Long-term visual acuity outcomes after radiation therapy for sporadic optic pathway glioma. J Neurooncol. 2019; 144:603–610. PMID: 31414376.
17. Parvez K, Parvez A, Zadeh G. The diagnosis and treatment of pseudoprogression, radiation necrosis and brain tumor recurrence. Int J Mol Sci. 2014; 15:11832–11846. PMID: 24995696.
18. Ludmir EB, Mahajan A, Paulino AC, Jones JY, Ketonen LM, Su JM, et al. Increased risk of pseudoprogression among pediatric low-grade glioma patients treated with proton versus photon radiotherapy. Neuro Oncol. 2019; 21:686–695. PMID: 30753704.
19. Han Y. Current status of proton therapy techniques for lung cancer. Radiat Oncol J. 2019; 37:232–248. PMID: 31918460.
20. Wan MJ, Ullrich NJ, Manley PE, Kieran MW, Goumnerova LC, Heidary G. Long-term visual outcomes of optic pathway gliomas in pediatric patients without neurofibromatosis type 1. J Neurooncol. 2016; 129:173–178. PMID: 27311725.
21. Avery RA, Hardy KK. Vision specific quality of life in children with optic pathway gliomas. J Neurooncol. 2014; 116:341–347. PMID: 24197987.
22. Shofty B, Mauda-Havakuk M, Weizman L, Constantini S, Ben-Bashat D, Dvir R, et al. The effect of chemotherapy on optic pathway gliomas and their sub-components: a volumetric MR analysis study. Pediatr Blood Cancer. 2015; 62:1353–1359. PMID: 25858021.
23. Kelly JP, Weiss AH. Detection of tumor progression in optic pathway glioma with and without neurofibromatosis type 1. Neuro Oncol. 2013; 15:1560–1567. PMID: 24101736.
24. Grabenbauer GG, Schuchardt U, Buchfelder M, Rödel CM, Gusek G, Marx M, et al. Radiation therapy of optico-hypothalamic gliomas (OHG)--radiographic response, vision and late toxicity. Radiother Oncol. 2000; 54:239–245. PMID: 10738082.
25. Greenberger BA, Pulsifer MB, Ebb DH, MacDonald SM, Jones RM, Butler WE, et al. Clinical outcomes and late endocrine, neurocognitive, and visual profiles of proton radiation for pediatric low-grade gliomas. Int J Radiat Oncol Biol Phys. 2014; 89:1060–1068. PMID: 25035209.
26. Hanania AN, Paulino AC, Ludmir EB, Shah VS, Su JM, McGovern SL, et al. Early radiotherapy preserves vision in sporadic optic pathway glioma. Cancer. 2021; 127:2358–2367. PMID: 33739455.
27. Awdeh RM, Kiehna EN, Drewry RD, Kerr NC, Haik BG, Wu S, et al. Visual outcomes in pediatric optic pathway glioma after conformal radiation therapy. Int J Radiat Oncol Biol Phys. 2012; 84:46–51. PMID: 22607912.
28. Mueller S, Fullerton HJ, Stratton K, Leisenring W, Weathers RE, Stovall M, et al. Radiation, atherosclerotic risk factors, and stroke risk in survivors of pediatric cancer: a report from the Childhood Cancer Survivor Study. Int J Radiat Oncol Biol Phys. 2013; 86:649–655. PMID: 23680033.
29. Bavle A, Srinivasan A, Choudhry F, Anderson M, Confer M, Simpson H, et al. Systematic review of the incidence and risk factors for cerebral vasculopathy and stroke after cranial proton and photon radiation for childhood brain tumors. Neurooncol Pract. 2021; 8:31–39. PMID: 33664967.
30. Merchant TE, Kun LE, Wu S, Xiong X, Sanford RA, Boop FA. Phase II trial of conformal radiation therapy for pediatric low-grade glioma. J Clin Oncol. 2009; 27:3598–3604. PMID: 19581536.
31. Kestle JR, Hoffman HJ, Mock AR. Moyamoya phenomenon after radiation for optic glioma. J Neurosurg. 1993; 79:32–35. PMID: 8315466.
32. Mueller S, Sear K, Hills NK, Chettout N, Afghani S, Gastelum E, et al. Risk of first and recurrent stroke in childhood cancer survivors treated with cranial and cervical radiation therapy. Int J Radiat Oncol Biol Phys. 2013; 86:643–648. PMID: 23623405.
Article
33. El-Fayech C, Haddy N, Allodji RS, Veres C, Diop F, Kahlouche A, et al. Cerebrovascular diseases in childhood cancer survivors: role of the radiation dose to Willis circle arteries. Int J Radiat Oncol Biol Phys. 2017; 97:278–286. PMID: 28068236.
34. Campen CJ, Kranick SM, Kasner SE, Kessler SK, Zimmerman RA, Lustig R, et al. Cranial irradiation increases risk of stroke in pediatric brain tumor survivors. Stroke. 2012; 43:3035–3040. PMID: 22968468.
Article
35. Bowers DC, Mulne AF, Reisch JS, Elterman RD, Munoz L, Booth T, et al. Nonperioperative strokes in children with central nervous system tumors. Cancer. 2002; 94:1094–1101. PMID: 11920480.
Article
36. Lee KA, O’Sullivan C, Daly P, Pears J, Owens C, Timmermann B, et al. Proton therapy in paediatric oncology: an Irish perspective. Ir J Med Sci. 2017; 186:577–582. PMID: 27744643.
Article
37. Kralik SF, Watson GA, Shih CS, Ho CY, Finke W, Buchsbaum J. Radiation-induced large vessel cerebral vasculopathy in pediatric patients with brain tumors treated with proton radiation therapy. Int J Radiat Oncol Biol Phys. 2017; 99:817–824. PMID: 28867358.
Article
38. Hall MD, Bradley JA, Rotondo RL, Hanel R, Shah C, Morris CG, et al. Risk of radiation vasculopathy and stroke in pediatric patients treated with proton therapy for brain and skull base tumors. Int J Radiat Oncol Biol Phys. 2018; 101:854–859. PMID: 29730064.
Article
39. Brauner R, Malandry F, Rappaport R, Zucker JM, Kalifa C, Pierre-Kahn A, et al. Growth and endocrine disorders in optic glioma. Eur J Pediatr. 1990; 149:825–828. PMID: 2226566.
Article
40. Lacaze E, Kieffer V, Streri A, Lorenzi C, Gentaz E, Habrand JL, et al. Neuropsychological outcome in children with optic pathway tumours when first-line treatment is chemotherapy. Br J Cancer. 2003; 89:2038–2044. PMID: 14647135.
Article
41. Papini C, Dineen RA, Walker DA, Thomas S, Pitchford NJ. Neuropsychological outcomes of children with optic pathway glioma. Sci Rep. 2020; 10:3344. PMID: 32094393.
Article
42. Janss AJ, Grundy R, Cnaan A, Savino PJ, Packer RJ, Zackai EH, et al. Optic pathway and hypothalamic/chiasmatic gliomas in children younger than age 5 years with a 6-year follow-up. Cancer. 1995; 75:1051–1059. PMID: 7842408.
Article
43. Jalali R, Mallick I, Dutta D, Goswami S, Gupta T, Munshi A, et al. Factors influencing neurocognitive outcomes in young patients with benign and low-grade brain tumors treated with stereotactic conformal radiotherapy. Int J Radiat Oncol Biol Phys. 2010; 77:974–979. PMID: 19864079.
Article
44. Redmond KJ, Mahone EM, Terezakis S, Ishaq O, Ford E, McNutt T, et al. Association between radiation dose to neuronal progenitor cell niches and temporal lobes and performance on neuropsychological testing in children: a prospective study. Neuro Oncol. 2013; 15:360–369. PMID: 23322748.
Article
45. Qi XS, Stinauer M, Rogers B, Madden JR, Wilkening GN, Liu AK. Potential for improved intelligence quotient using volumetric modulated arc therapy compared with conventional 3-dimensional conformal radiation for whole-ventricular radiation in children. Int J Radiat Oncol Biol Phys. 2012; 84:1206–1211. PMID: 22516805.
Article
46. Park J, Park Y, Lee SU, Kim T, Choi YK, Kim JY. Differential dosimetric benefit of proton beam therapy over intensity modulated radiotherapy for a variety of targets in patients with intracranial germ cell tumors. Radiat Oncol. 2015; 10:135. PMID: 26112360.
Article
47. Rotta JM, de Oliveira MF, Reis RC, Botelho RV. Malignant transformation of low-grade gliomas in patients undergoing adjuvant therapy. Acta Neurol Belg. 2017; 117:235–239. PMID: 27271289.
Article
48. Broniscer A, Baker SJ, West AN, Fraser MM, Proko E, Kocak M, et al. Clinical and molecular characteristics of malignant transformation of low-grade glioma in children. J Clin Oncol. 2007; 25:682–689. PMID: 17308273.
Article
49. Deng MY, Sturm D, Pfaff E, Sill M, Stichel D, Balasubramanian GP, et al. Radiation-induced gliomas represent H3-/IDH-wild type pediatric gliomas with recurrent PDGFRA amplification and loss of CDKN2A/B. Nat Commun. 2021; 12:5530. PMID: 34545083.
Article
50. Hall EJ. Intensity-modulated radiation therapy, protons, and the risk of second cancers. Int J Radiat Oncol Biol Phys. 2006; 65:1–7. PMID: 16618572.
Article
51. Tringale KR, Casey DL, Niyazov G, Lavery JA, Moskowitz C, Friedman DN, et al. Second cancer risk in childhood cancer survivors treated with intensity-modulated radiation therapy: an updated analysis of more than 10 years of follow-up. Pediatr Blood Cancer. 2022; 69:e29600. PMID: 35234340.
Article
52. Brodin NP, Munck Af Rosenschöld P, Aznar MC, Kiil-Berthelsen A, Vogelius IR, Nilsson P, et al. Radiobiological risk estimates of adverse events and secondary cancer for proton and photon radiation therapy of pediatric medulloblastoma. Acta Oncol. 2011; 50:806–816. PMID: 21767178.
Article
53. Indelicato DJ, Bates JE, Mailhot Vega RB, Rotondo RL, Hoppe BS, Morris CG, et al. Second tumor risk in children treated with proton therapy. Pediatr Blood Cancer. 2021; 68:e28941. PMID: 33565257.
Article
54. Chung CS, Yock TI, Nelson K, Xu Y, Keating NL, Tarbell NJ. Incidence of second malignancies among patients treated with proton versus photon radiation. Int J Radiat Oncol Biol Phys. 2013; 87:46–52. PMID: 23778197.
Article
Full Text Links
  • BTRT
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr